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Proteinuria and functional characteristics of the glomerular bar-
rier in diabetic nephropathy. Fractional clearances of uncharged
dextran 40 and anionic proteins were performed in an attempt to
elucidate the defect in glomerular barrier function responsible for
heavy proteinuria in diabetic nephropathy. Notwithstanding uri-
nary albumin excretion (UaIbV) at 3634 608 g/min, the frac-
tional clearance for dextran molecules with Einstein-Stokes radii
(r) between 22 and 36 A was depressed in 12 patients with ad-
vanced diabetic nephropathy, which suggests a reduction in
mean glomerular pore size or density. Equivalent restriction to
transglomerular passage of dextrans with a r < 36 A in 7 patients
with minimal change nephropathy was associated with a similar-
ly enhanced proteinuria (UIbV, 3333 759 g/min). The dis-
sociation between fractional clearances for neutral and anionic
macromolecules in both disorders is consistent with loss of gb-
merular electrostatic charge. In diabetic nephropathy, however,
the fractional clearances for large dextrans and test proteins con-
siderably exceeded corresponding values in minimal change ne-
phropathy when r  36 A. Furthermore, the fractional clear-
ances for test proteins were two orders of magnitude smaller than
that for equivalent-sized dextrans in minimal change nephropa-
thy, whereas this difference was much less in diabetic nephropa-
thy. Thus, a selective increase in transglomerular passage of
large molecules and a progressive loss of ability to discriminate
between large molecules of different configuration distinguish the
gbomerular capillary wall in diabetic nephropathy from that in
minimal change nephropathy.
Protéinurie et caractéristiques fonctionnelies de Ia barrière
gbomérulaire dans Ia néphropathie diabetique. Les clearances
fractionnelles de dextran 40 neutre Ct de protéines anioniques
ont été mesurées afin d'étudier le défaut de Ia fonction de Ia
barrière glomerulaire responsable de Ia protéinurie massive au
cours de Ia nephropathie diabétique. Malgré une excretion un-
naire d'albumine (UaJbV) de 3634 608 ug/min, Ia clearance frac-
tionnelle pour les molecules de dextran dont Ic rayon d'Einstein-
Stokes (r) Ctait compnis entre 22 et 36 A Ctait abaissé chez 12
malades atteints de nephropathie diabCtique avancée, cc qui sug-
gère une diminution de Ia taille moyenne ou de Ia densité des
pores. Une diminution équivalente de Ia restriction au fran-
chissement du gbomérule de dextran r < 36 A chez 7 malades
atteints de néphropathie a modifications minimes était associée
a une protéinunie du mCme ordre (UaIbV, 3333 759 g/min). La
dissociation entre les clearances fractionnelles des macromolC-
cules neutres et anioniques dans les deux affections est compat-
ible avec une perte des charges electrostatiques glomCrulaires.
Dans Ia néphropathie diabCtique, cependant les clearances frac-
tionnelles des dextrans de grande taille et des protCines Ctudiées
Ctait plus Cievé que les valeurs obtenues dans les néphropathies
a modifications minimes quand r  36 A. Dc plus, les clearances
fractionnelles pour les protéines étudiées sont plus es petit de
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deux ordres de grandeur que les clearances fractionnelles pour
les dextrans de taille equivalente dans Ia néphropathie a modifi-
cations minimes, abors que cette difference était bien moindre dans
Ia nCphropathie diabCtique. Ainsi une augmentation selective du
passage transglomerulaire des grosses molecules et une perte
progressive de Ia capacité de discniminer entre les grosses mole-
cules scion leur configuration différencie Ia paroi du capillaire
gbomerulaire de Ia néphropathie diabetique de ceile de Ia néphro-
pathie a modifications minimes.
Heavy proteinuria is the clinical hallmark of dia-
betic nephropathy. It is associated with (1) long-
standing, insulin-requiring diabetes, usually of more
than 10 years' duration [1-4], (2) depression of the
rate of glomerular ultrafiltration (GFR) [4, 5],(3) ad-
vanced diabetic glomerulosclerosis, invariably of
the diffuse and sometimes also of the nodular type
[6-9], and (4) abnormal biochemical composition of
isolated glomeruli characterized by an increase in
hydroxylysine-disaceharide-linked residues [10].
From a functional standpoint, the glomerular cap-
illary wall generally has been viewed as a porous
molecular sieve capable of permitting essentially
free filtration of water and "small" plasma solutes
while restricting the passage of large molecules in-
cluding plasma proteins. According to this view,
emphasized initially by Pappenheimer, Renkin, and
Borrero [11] and Landis and Pappenheimer [12], re-
striction to transport of certain molecules across a
limiting barrier is based on the assumption that the
barrier is perforated by slits or cylindrical pores.
With fractional clearances of macromolecules, it
has been possible to calculate an average pore radi-
us of approximately 52 A for the glomerular capil-
lary wall in both normal humans [13, 14] and Mu-
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nich-Wistar rats [15, 16]. Although no such pores
can be seen on electron microscopy, the local-
ization of electron-dense tracers beneath the gb-
merular basement membrane and at the filtration
slit diaphragms has led workers to propose that
these structures constitute the major barriers to the
filtration of macromolecules in the three-layered
glomerular capillary wall [17, 19].
Given the profound structural, functional, and
biochemical alterations in the glomerular capillary
wall in diabetic nephropathy, it has been postulated
that an increase in effective pore size permits the
escape of plasma proteins into the urine in this dis-
order [20-22]. Recent studies of human and experi-
mental glomerular diseases, however, have demon-
strated that proteinuria can be attributed to altera-
tions in properties of the glomerular filter other than
those related to pore size [23—25]. In these glomeru-
lar diseases, proteinuria and enhanced clearance of
anionic macromolecules have been found in the
presence of a reduction in mean pore size or den-
sity, suggesting that a key alteration is a deficiency
in electrostatic repulsion of negatively charged
macromolecules by the diseased glomerular capil-
lary wall.
Accordingly, we attempted to define the function-
al characteristics of the glomerular barrier in pa-
tients with diabetic nephropathy by performing
fractional clearances with three test macromole-
cules that differ with respect to size, charge, and
shape. They were (1) dextran 40 (Rheomacrodex,
Pharmacia Fine Chemicals AB), a series of un-
charged and loosely coiled polymers, the com-
ponent molecules of which have Einstein-Stokes
radii (r) varying between 20 and 57 A; (2) endoge-
nous albumin (alb), a globular protein with a well-
defined molecular size (r = 36 A) and charge (iso-
electric point, 4.8); and (3) endogenous immuno-
globulin G (IgG), a larger protein (r = 50 A), the
component subclasses of which have isoelectric
points varying between 6.4 and 7.2.
Methods
Study population. Twelve patients with diabetic
nephropathy and 19 controls were studied. The
study protocol and informed consent procedure
were approved by the Stanford University Com-
mittee for the Protection of Human Subjects in Re-
search.
Experimental group. This group consisted of 12
patients with diabetes who had proteinuria rang-
ing from 2.5 to 12 g/day. The criterion for accept-
ance into the experimental group was the opthal-
moscopic evidence of diabetic retinopathy in a pa-
tient with heavy proteinuria (> 2 g/day) because the
almost invariable coexistence of diabetic reti-
nopathy with diabetic glomerulosclerosis permits
the diagnosis of diabetic nephropathy to be made
without resort to renal biopsy [26—28]. The 8 males
and 4 females in this group varied in age from 32 to
60 years.
Control groups. The controls comprised three
groups, 12 males and 7 females, whose ages (be-
tween 18 and 63 years) were similar to those in the
diabetic experimental group. Group 1. This group
was composed of 7 healthy volunteers who were de-
void of renal disease and hypertension as judged by
a negative history, clinical examination, and urinal-
ysis. Group 2. Five nonnephrotic patients with ad-
vanced but stable chronic renal diseases (CRD)
were selected for study because their GFR's were
depressed over a range similar to that in diabetic
patients (8 to 60 mI/min/ 1.73 m2). Their urinary pro-
tein excretion rates were modest, amounting to < 2
g/day. Their underlying renal diseases included
polycystic kidney disease (N = 2), hypertension
with nephrosclerosis (N = 1), chronic tubulo-
interstial disease (N = 1), and chronic lupus neph-
ntis (N = 1). The latter two diagnoses were con-
firmed by renal biopsy. Group 3. This group com-
prised 7 patients in whom a nephrotic syndrome
was associated with biopsy-proven minimal change
nephropathy (MCN). This discreet variety of the
nephrotic syndrome was selected for study be-
cause, unlike diabetic nephropathy, glomerular
structure is only minimally and reversibly altered.
Study protocol. Each subject was required to
empty his or her bladder, by voiding, before receiv-
ing an i.v. injection containing inulin (60 mg/kg),
PAH (36 mg/kg), and dextran 40 (130 mg/kg). Fol-
lowing this injection, a high rate of urine flow was
induced by oral water loading. At the end of a 40- to
60-mm equilibration period, their bladders were
again emptied by voiding; then, three to five care-
fully timed urine collections were made. Venous
blood was sampled at 5, 10, 20, and 40 mm follow-
ing the test solute infusion and thereafter at the be-
ginning and end of each urine collection.
Inulin and PAH clearances were calculated from
the average clearance value or all timed collection
periods by using the equation
= (U/P)• V/1.73 m2 (I)
where (U/P) is the urine/plasma solute (inulin and
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PAH) concentration ratio, and V is the urine flow
rate expressed in milliliters per minute. P, the mid-
collection-point plasma solute concentration, was
calculated from the plasma inulin and PAH concen-
tration curves [29].
The fractional clearance (0) was determined for
each of the three test macromolecules (M), with in-
ulin (In) as the reference solute, from the equation
= (U/P)M/(U/P)Ifl (2)
where (U/P)M is the urine/plasma concentration ratio
for each test macromolecule, and (U/P)1 were de-
termined from urine and plasma from the initial col-
lection period. The urinary albumin (UalbV) and IgG
(UjgGV) excretion rates (expressed in micrograms
per minute) were calculated from the product of the
respective urinary concentration of each protein
(expressed in milligrams per deciliter) and the urine
flow rate (expressed in milliliters per minute).
Laboratory determinations. For the calculation
of GFR, the inulin concentration in urine and
plasma from each collection period was determined
by the autoanalyzer method of Fjelbo and Stamey
[30]. This method uses the fructose-specific reagent
resorcinol, and we have found it to be uninfluenced
by the presence of dextran. The autoanalyzer meth-
od of Harvey and Brothers, which uses Marshall re-
agent, was used for the determination of PAH con-
centrations [31]. Following gel permeation chroma-
tography of plasma and urine. eluted fractions were
assayed for dextran and inulin concentration by a
modification of the autoanalyzer Anthrone method
of Scott and Melvin [32]. Dextran standards were
prepared for assaying the early dextran-containing
fractions (nos. 30 to 45). Separate inulin standards
were used for assay of the smaller inulin molecules
(r = 11 to 17 A) that appeared in late eluted frac-
tions (nos. 48 to 57).
Albumin and IgG concentrations in plasma and
urine were determined by radial immunodiffusion
(Kallestad Labs, Inc.) [33]. Test protein concentra-
tions in unconcentrated urine were determined by
using low-level immunodiffusion plates (Endoplates
albumin or IgG cerebrospinal fluid test kit, Kalles-
tad Labs, Inc.). These plates permit the measure-
ment of these proteins over a concentration range of
4 to 100 mg/dl for albumin and ito 25 mg!dl for IgG.
To ensure that heavy chain-containing degradation
products of IgG did not spuriously elevate urinary
IgG concentration, we tested 25- to 100-fold con-
centrated urine samples from 5 patients with diabet-
ic nephropathy against heavy- and light-chain anti-
sera by the double-diffusion Ouchterlony technique
and by immunoelectrophoresis [33]. Plasma oncotic
pressure () was determined with a Weil oncometer
(Instrumentation Laboratories, model IL- 186).
Chromatographic procedures. Separation of dex-
tran 40 in plasma and urine into narrow fractions
(approximately 2 A) was accomplished by gel per-
meation chromatography with Sephacryl S200. Two
columns, 91 and 95 cm in length, with internal diam-
eters of 1.6 cm, were used. Each column was cali-
brated with three narrow dextran fractions of
known molecular size (provided by Pharmacia Fine
Chemicals AB, Uppsula, Sweden). Using 0.3% sa-
line as eluant, we collected 2.6 ml of eluted frac-
tions with an automatic fractionator (Gilson). The
void volume (V0) was determined with blue dex-
tran, and the fractional volume available to the sol-
ute (Kay) was then calculated as
Kay = (Ve — V0)/(V — V0) (3)
where Ve is the elution volume of the solute, and Vt
is the total volume of the gel column [34]. Stokes-
Einstein radii (r) for individual dextran fractions
were calculated from Kay [35].
Statistical methods. All results are expressed as
the means SEM. Student's t test for unpaired
data was used to evaluate differences between the
experimental and control groups.
Results
Clinical and laboratory findings. The onset of di-
abetes mellitus preceded the study by 6 to 33 years
in the diabetic patients, 10 of whom were requiring
insulin, and 2 of whom were receiving oral hypogly-
cemic agents. Pertinent laboratory findings for
these patients are summarized and compared with
those of the control groups in Table 1. Inulin and
PAH clearances were depressed below 30 and 150
mlIminIl.73 m2, respectively, in all but 2 diabetic
patients, and were significantly lower, on average,
than the corresponding values in normal volunteers
and in patients with MCN. Mean inulin (18 5 ml!
mm/i .73 m2) and PAH clearances (80 24 mL/min!
1.73 m2) in diabetic patients were also somewhat
lower than they were in CRD control patients, but
these differences did not reach statistical signifi-
cance.
Mean UajbV in patients with diabetic nephropa-
thy was similar to that in nephrotic patients with
MCN (3634 608 vs. 3333 759 g!min) but was
more than threefold larger than in patients with
CRD. Mean UIgGV, which averaged 596 132 /.Lg!
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mm in diabetic nephropathy, was elevated ninefold
and sixfold, respectively, above the corresponding
values in patients with MCN and CRD.
Fractional dextran clearances (Fig. I and Table
2). The fractional clearance values of dextran 40 rel-
ative to inulin (On) plotted as a function of the Ein-
stein-Stokes radius (r) are illustrated for all four
study groups in Fig. I. The results of normal control
subjects (Fig. la and Table 2) are similar to those
reported by others in man [14, 36]. Measureable re-
striction to dextran indicated by O falling below
unity occurred when r> 22 A. With increasing mo-
lecular size, 0D declined and approached zero for
dextrans with r > 48 A. Despite massive protein-
uria, the mean fractional dextran clearance profile
in diabetic nephropathy was depressed below that
of normal controls in the dextran r interval 24 to 36
A (Fig. la and Table 2). OD was also depressed rela-
tive to control patients with CRD, the depression
being evident over the entire range of molecular siz-
es examined (r = 22 to 48 A, Fig. Ib). Although 6D
for dextran molecules with r < 36 A was similarly
depressed in patients with diabetic nephropathy and
in those with minimal change nephropathy, 6D for
larger molecules was significantly higher in diabetic
than in minimal change nephropathy patients. (Fig.
Ic and Table 2).
Fractional protein clearances. To permit com-
parison between glomerular proteinuria and the gb-
merular filtration of dextrans, we calculated frac-
tional protein clearances for patients with diabetic
nephropathy and for nephrotic controls with MCN.
The accuracy of this calculation requires that
heavy-chain reactivity measured by radial immuno-
diffusion reflects intact IgG. In urine samples from 5
diabetic patients, immunoelectrophoresis revealed
all detectable light and heavy chains of IgG to have
the same electrophoretic mobility as intact plasma
IgG. Furthermore, reactions of identity were ob-
tamed with isolated polyclonal human IgG when the
urinary IgG was examined by the Ouchterlony
double-diffusion technique of using antihuman anti-
bodies specific for IgG heavy chains and for kappa
and lambda light chains (Meloy Labs, Inc.). Thus,
IgG fragments were not detectable by either method
in urine samples from these diabetic patients. These
findings are in keeping with the more quantitative
data of Petersen et al, who used gel permeation
chromatography combined with immunodiffusion.
They found intact urinary IgG and Fc fragments to
account for 98.8 and 1.2%, respectively, of immu-
noreactivity to a heavy-chain-specific IgG antibody
in patients with glomerular proteinuria [37].
The relationship between fractional clearance of
test proteins and dextrans of equivalent size is illus-
trated in Fig. 2. The 6alb in patients with minimal
change nephropathy averaged 1.75 0.59 x l0-, a
value 110 times smaller than that for 6D36 (0.19
0.02). Similarly, 0ISG, which averaged 1.3 0.4 x
was 230 times less than 9D for a dextran mole-
cule with r = 48 A, which averaged 0.03 0.01. In
patients with diabetic nephropathy, Oa1, and
were one order of magnitude larger than the corre-
sponding values in MCN, averaging 1.305 0.270
x 10 and 6.43 1.47 x 10, respectively. Thus,
the discrepancy between the fractional clearances
of the two test species was much less in diabetic
than it was in minimal change nephropathy.
Discussion
Although proteinuria seldom appears before 10
years have elapsed from the onset of juvenile diabe-
tes mellitus, quantitative electron microscopy has
revealed thickening of the GBM within 5 years [38.-
40]. To determine whether glomerular permselec-
tivity to macromolecules was altered at this early
stage, Mogensen studied a group of patients with
juvenile diabetes, the duration of which was 5
Table 1. Laboratory findings in patients with diabetic nephropathy and in controlsa
Groups
C1 CPAH
'if
mm Hg
UaiV UIgGV
mlIminII.73 m2 p.g/min
Diabetic nephropathy (N = 12) 18 80 20.0 3634 596
Control groups
(1) Normal volunteers (N = 7) 99" 513" 277b ND ND
(2) Chronic renal disease (N = 5) 31 111 27.2" 1076" 102"
(3) Minimal change nephropathy 80" 371" 17.6 3333 65"(N = 7)
a Values are the means SEM. ir is plasma oncotic pressure. ND is not detectable.
"P < 0.05, compared with the diabetic nephropathy group.
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Fig. 1. Fractional dextran clearance profile (mean SEM) in dia-
betic nephropathv (.) compared with: (A) normal subjects ([0],
upper panel), (B) patients with nonnephrotic chronic renal dis-
ease (LDI, middle panel), and (C) minimal change nephropathy
([s], lower panel).
years. He found that the fractional dextran clear-
ance profile was not different from that in a group of
healthy control persons [36]. Although our data for
dextran clearances confirm earlier observations that
massive proteinuria persists in diabetic nephropa-
thy even when GFR declines to very low levels [9,
41], they fail to provide evidence for an increase in
average glomerular porosity in the late stages of this
disorder. The clearance of PAH, and hence presum-
ably mean glomerular plasma flow, was profoundly
depressed in these diabetic patients, a finding pre-
dicted to elevate rather than depress the fractional
dextran clearance profile [42]. Of the driving pres-
sures for glomerular filtration, only plasma (af-
ferent) oncotic pressure can be determined in man.
This quantity was depressed to 72% of that in nor-
mal controls (Table 1). Although this change, by it-
self, is unlikely to have any measureable effect on
glomerular permselectivity to macromolecules [15,
43], it might favor an increase in net glomerular ul-
trafiltration pressure, which could reduce the per-
meation of dextrans into Bowman's space. Thus,
even though an alteration in glomerular capillar he-
modynamics cannot be excluded as a cause for the
observed depression of the fractional dextran clear-
ance profile in diabetic nephropathy, a reduction in
mean glomerular pore size or density would seem to
provide a more likely explanation.
Because charged preparations of dextran are not
available for use in humans, we attempted to eluci-
date glomerular permselectivity in our nephrotic pa-
tients by using the endogenous proteins albumin
and IgG as test macromolecules. That the fractional
clearances of these proteins reflect their glomerular
sieving coefficients requires the assumption that
tubular reabsorption is negligible or, if substantial,
then nonselective in nephrotic patients. Tubular
reabsorption results in less than 10% of filtered pro-
teins appearing in the urine of normal persons, thus
limiting the usefulness of fractional clearance for
determining glomerular permselectivity [44]. Re-
cent micropuncture studies in the rat, however, in-
dicate that when the filtration of albumin is sub-
stantially increased by glomerular injury, the tubu-
lar reabsorptive mechanism rapidly becomes
saturated, with the result that nearly all filtered al-
bumin is excreted in the urine [45, 46].
Normally, the glomerular sieving coefficient for
albumin is considerably lower than that of an un-
charged dextran molecule with an equivalent hydro-
dynamic radius (36 A). That relative restriction of
albumin, a polyanion, is in part due to its negative
charge has been demonstrated by the studies of
Chang et al using fractional neutral dextran and
dextran sulfate clearances in the normal Munich-
Wistar rat [47]. There was a reduction in fractional
clearance of dextran sulfate, an anionic polymer,
over a range of molecular radii from 18 to 42 A
when compared to that of uncharged dextran of
equivalent molecular size. The fractional clearance
of dextran sulfate with an effective radius of 36 A
was 0.01 as compared to 0.19 for uncharged dextran
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of equivalent size, suggesting that molecular charge
is an important determinant of glomerular permse-
lectivity to macromolecules and that electrostatic
interaction between anionic molecules and the neg-
atively charged glomerular capillary wall may be an
important feature of the permselective properties of
the glomerular capillary wall.
Proteins also differ in shape from dextrans of
equivalent size. Recent micropuncture studies in-
dicate that the concentration of albumin in Bow-
man's space in the normal rat varies between I and
3 mgldl [45, 46]. From these values it can be calcu-
lated that the glomerular sieving coefficient is less
than 0.001, a value considerably smaller than that
for anionic dextran sulfate with an identical Ein-
stein-Stokes radius. A possible explanation for this
size- and charge-independent enhancement of
transglomerular dextran transport relates to its con-
figuration. It has been suggested that dextran mole-
cules, in contrast to globular proteins, are deform-
able and elastically compliant under the shear
stresses imposed during convective flow through
the glomerular membrane [48, 49]. Thus, these
molecules may be deformed to elongated shapes
and thus pass through pores far more easily than
their unperturbed dimensions in solution might sug-
gest.
Our finding of restricted transglomerular dextran
transport in the presence of heavy proteinuria in
diabetic nephropathy is similar to that already de-
scribed in several other glomerular injuries, includ-
ing MCN and glomerulonephritis in man [23, 50],
and aminonucleoside nephropathy and nephrotoxic
serum nephritis in the rat [24, 25]. The glomerular
polyanion thought to be responsible for normal
electrostatic retardation of anionic macromolecules
is a sialic acid containing glycoprotein, which has
been found to be depleted in both MCN [51] and in
diabetic nephropathy [52, 53]. Loss of the elec-
trostatic barrier may therefore contribute to the
30 40 50
Einstein-Stokes radius, A
Fig. 2. Fractional macrotnolecule clearance profiles in diabetic
nephropathy (S = dextran, E = protein) and ,nini,nal change
nephropathy ( = dextran. = protein). Also shown is the frac-
tional dextran clearance profile in normal subjects (0).
proteinuria in our patients with these two dis-
orders.
The characteristics of the glomerular barrier in
diabetic nephropathy differ from those in MCN,
however, in two respects. Whereas the depression
of 0D in the interval 20 to 36 A relative to normal
persons was similar, 0D for r> 36 A was elevated in
diabetic nephropathy relative to MCN (Fig. 2). In
addition to increasing O for larger dextran mole-
cules, diabetic nephropathy was associated with
Table2. Fractional dextran clearances in patients with diabetic nephropathyand in controls
Groups 20A 24A 28A 32A 36A 40A 44A 48A
Diabetic nephropathy 0.99 0.72 0.52 0.36 0.23 0.14 0.08 0.04
Control groups
(1) Normalvolunteers 0.97 0.80k' 062b 044b 0.26k 0.15 0.07 0.04
(2) Chronicrenal 0.98 0,85b 0.64 0.48b 0.33b 0.2lb 013b 007b
disease ±0.03 ±0.03 ±0.04 ±0.04 ±0.03 ±0.02 ±0.02 ±0.02
(3) Minimalchange 0.89 0.68 0.51 0.32 0.19 0.11" 0.05" 0.03
nephropathy ±0.07 ±0.06 ±0.05 ±0.03 ±0.02 ±0.01 ±0.01 ±0.01
a Values are the means ± SEM.
P < 0.05, compared with the diabetic nephropathy group.
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progressive loss of discrimination between the test
proteins and dextran molecules of equivalent size.
Fractional clearance of dextran (r = 36 A) was 110
times that for albumin (r = 36A), whereas fractional
clearance of dextran (r = 48 A) was 230 times that
of IgG (r = 50 A) in minimal change nephropathy.
In contrast, these differences were much less in dia-
betic nephropathy, being 18- and 7-fold, respective-
ly (Fig. 2). Although a loss of the charge selective
properties of the glomerular capillary wall might
contribute to the proteinuria of both MCN and DN,
there also appears to be a loss of shape discrimina-
tion in diabetic nephropathy.
The presence of a few isolated membrane defects
permitting the unrestricted passage of large plasma
proteins, combined with a shift in distribution of
pores to those of smaller size, might account for our
findings in diabetic nephropathy. A shift to smaller
pore size would explain the depression of fractional
dextran clearances (r < 36 A) but not the normal
fractional clearances of larger dextran molecules (r
= 40 to 48 A). Ideally, if this hypothesis of a few
scattered large membrane defects superimposed on
a shift to pores of smaller size were true, the frac-
tional clearance for dextrans with a r> 50 A would
be predicted to decline to a finite and constant value
between 0 and 0.04. In contrast, 0D for progressive-
ly large molecules above 50 A in normal controls
would be predicted to decline asymptotically to-
wards zero. Given the low concentration of appro-
priately large dextran molecules in the injectate and
the analytical error involved in the determination of
urinary dextran concentration at such low clearance
rates, we have not been able to test this hypothesis,
which must, therefore, remain speculative. It is
noteworthy, however, that a focal foot-process de-
generation with detachment of epithelial cells and
denudation of the underlying GBM has recently
been described in advanced diabetic nephropathy
[54]. This process may totally disrupt the glomeru-
lar barrier to filtration of proteins and hence provide
a structural basis for large membrane defects that
do not discriminate among size, charge, or shape of
macromolecules. Further investigation of human or
experimental diabetic nephropathy, combining a
structural approach with fractional clearances of
larger test macromolecules, will be required to ex-
plore this hypothesis and to define more precisely
the mechanism of proteinuria in this disorder.
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